Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X4MN
|
|||
| Former ID |
DNCL003418
|
|||
| Drug Name |
CC-930
|
|||
| Synonyms |
TANZISERTIB; CC-930; 899805-25-5; CC 930; UNII-M5O06306UO; CHEMBL1950289; M5O06306UO; CC930; Trans-4-({9-[(3s)-Tetrahydrofuran-3-Yl]-8-[(2,4,6-Trifluorophenyl)amino]-9h-Purin-2-Yl}amino)cyclohexanol; Tanzisertib [USAN:INN]; 3tti; trans-4-((9-((3S)-Tetrahydrofuran-3-yl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)cyclohexanol; Tanzisertib (USAN); CC-930(Tanzisertib); SCHEMBL2133061; SCHEMBL4760419; SCHEMBL2133055; GTPL9836; SCHEMBL8082102; SCHEMBL15589918; CHEMBL1950305; SCHEMBL10179476; JNK-930; MolPort-044-562-358
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discoid lupus erythematosus [ICD-11: EB51.0; ICD-10: L93.2] | Phase 2 | [1], [2] | |
| Idiopathic pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1] | Phase 2 | [1], [2] | ||
| Company |
Celgene
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H23F3N6O2
|
|||
| Canonical SMILES |
C1CC(CCC1NC2=NC=C3C(=N2)N(C(=N3)NC4=C(C=C(C=C4F)F)F)C5CCOC5)O
|
|||
| InChI |
1S/C21H23F3N6O2/c22-11-7-15(23)18(16(24)8-11)28-21-27-17-9-25-20(26-12-1-3-14(31)4-2-12)29-19(17)30(21)13-5-6-32-10-13/h7-9,12-14,31H,1-6,10H2,(H,27,28)(H,25,26,29)/t12?,13-,14?/m0/s1
|
|||
| InChIKey |
IBGLGMOPHJQDJB-MOKVOYLWSA-N
|
|||
| CAS Number |
CAS 899805-25-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Jun N terminal kinase (JNK) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01203943) A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT01466725) A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus. U.S. National Institutes of Health. | |||
| REF 3 | In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism. Xenobiotica. 2015;45(6):465-80. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.